Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn’s disease
Open Access
- 15 April 2019
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 49 (11) , 1401-1409
Abstract
Summary: Background: The appropriate location for biopsy procurement relative to an ulcer in active Crohn's disease is unknown.Aim: To explore the relationship between biopsy location, histological disease activity, proinflammatory gene expression and the presence of inflammatory cells.Methods: Fifty‐one patients with Crohn's disease and ulcers >0.5 cm diameter in the colon and/or ileum were prospectively enrolled at three centres. Biopsies were obtained from 0 mm, 7 to 8 mm and 21 to 24 mm from the edge of the largest ulcer. Histological activity was blindly assessed with the Global Histological Disease Activity Score, the Robarts Histopathology and Nancy Histological indices. Messenger ribonucleic acid (mRNA) levels for interleukins‐6, ‐8 and ‐23 (p19 and p40 subunits), CD31 and S100A9 were measured using quantitative polymerase chain reaction. The number of CD3+, CD68+ and myeloperoxidase‐positive cells was quantified by immunohistochemistry. Data were analysed using mixed models with location and segment as fixed effects and patients as random effect to account for correlation among segments within a patient.Results: Histological disease activity scores (P < 0.0001), proinflammatory gene expression levels (P < 0.005) and numbers of myeloperoxidase‐positive cells (P < 0.0001) were highest in biopsies from the ulcer edge in the colon and ileum, with decreasing gradients observed with distance from the edge (P < 0.05). No differences between colonic and ileal samples were detected for the parameters measured at any location.Conclusions: Biopsies from the ulcer edge in patients with Crohn's disease yielded the greatest histological disease activity and mRNA levels and had similar readouts in the colon and ileum. Research is needed to confirm this conclusion for other measures.Keywords
This publication has 40 references indexed in Scilit:
- Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseNew England Journal of Medicine, 2013
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's DiseaseGastroenterology, 2010
- Mucosal Gene Expression of Antimicrobial Peptides in Inflammatory Bowel Disease Before and After First Infliximab TreatmentPLOS ONE, 2009
- PECAM-1 (CD 31) mediates transendothelial leukocyte migration in experimental colitisAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2007
- The Montreal classification of inflammatory bowel disease: controversies, consensus, and implicationsGut, 2006
- Myeloperoxidase: friend and foeJournal of Leukocyte Biology, 2005
- Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CDGastrointestinal Endoscopy, 2004
- Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes.Gut, 1994
- Biopsy Studies in Ulcerative ColitisBMJ, 1956